脾脏硬度对初发骨髓增生异常综合征患者预后的影响

Effect of Spleen Stiffness Measurement on Prognosis of Patients with Primary Myelodysplastic Syndrome

目的探讨脾脏硬度(SSM)在骨髓增生异常综合征(MDS)患者预后中的意义。方法选取2016年2月-2020年3月在河北中石油中心医院就诊的40例初治MDS患者设为MDS组,同时选取18名健康志愿者设为对照组,分别进行SSM检测。比较两组SSM差异,进一步分析SSM与临床特征及预后的关系。结果MDS组SSM为[34.53(19.11~55.20)]kPa,高于对照组的[13.51(8.32~26.53)]kPa,差异有统计学意义(P<0.05);SSM<30 kPa及SSM≥30 kPa间ECOG评分、危险度分级、原始细胞比例、血小板计数、EPO比较,差异有统计学意义(P<0.05);SSM<30 kPa及SSM≥30 kPa间年龄、CI、染色体核型、血红蛋白、铁蛋白比较,差异无统计学意义(P>0.05);不同SSM、危险度分级、原始细胞比例、染色体核型间EFS、OS比较,差异有统计学意义(P<0.05)。结论SSM与危险度分级、染色体核型、原始细胞比例等有关,或可用来评估MDS患者预后。

Objective To explore the role of spleen stiffness measurement(SSM)in the prognosis of patients with myelodysplastic syndrome(MDS).Methods From February 2016 to March 2020,40 newly diagnosed MDS patients in Hebei Central Hospital of Petroleum were selected as the MDS group,and 18healthy volunteers were selected as the control group.SSM tests were performed to compare the differences between the two groups,and further analyze the relationship between SSM and clinical characteristics and prognosis.Results The SSM of MDS group was[34.53(19.11-55.20)]kPa,which was higher than[13.51(8.32-26.53)]kPa of the control group,and the difference was statistically significant(P<0.05).There were significant differences in ECOG score,risk grade,proportion of primitive cells,platelet count and EPO between SSM<30 kPa and SSM≥30 k Pa(P<0.05);there was no significant difference in age,CI,chromosome karyotype,hemoglobin and ferritin between SSM<30 kPa and SSM≥30 k Pa(P>0.05).There were statistically significant differences in the comparison of EFS and OS among different SSMs,risk classification,proportion of primitive cells,and chromosome karyotypes(P<0.05).Conclusion SSM is related to risk classification,chromosome karyotype,proportion of primitive cells,or can be used to evaluate the prognosis of MDS patients.